Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

Trading Statement

RNS Number:9033F
Osmetech PLC
10 July 2006



Osmetech plc - Trading Update

Osmetech plc, the international healthcare diagnostics group will provide the
following update during its Extraordinary General Meeting at 11:00am today:

During the first six months of 2006, the Group has continued to build on the
strong sales growth achieved in 2005. Sales for the 6 month period ended 30 June
2006 are 36% ahead of the corresponding period in 2005.

The majority of sales relate to the Critical Care division where sales exceeded
$8.6m, up by 34% on the corresponding period in 2005, with sales increasing in
both human and veterinary markets.

As planned, in the first half of the year, Osmetech's Molecular Diagnostics
Division launched its FDA approved eSensor Cystic Fibrosis Carrier Detection
test and eSensor 4800 DNA Detection instrument and OPTI TUBE product for use in
the Roche LightCycler as a cost-effective and safe alternative to the Roche
glass capillaries. Our OPTI GENE instrument and proprietary consumable system
for the rapid detection of DNA and RNA targets will be launched with
thrombophilia assays at the American Association of Clinical Chemists (AACC)
Conference in Chicago later this month.

We are confident of further sales growth for the Group in the second half of the
year. We expect our Critical Care division to report a record sales performance
during the next six month period with a growing contribution from our new OPTI
LION and OPTI R instruments and further strong sales growth of the VetStat
product by our distribution partner, IDEXX, in the veterinary market. We also
expect to report early commercial success with our new molecular diagnostics
products as we start to build a significant presence in this rapidly growing
market.

Ends

Osmetech says US biotech fund Efficacy holds almost 9 pct of co

LONDON (AFX) - Diagnostics company Osmetech PLC said the Efficacy Biotech
Fund of California-based Efficacy Capital Ltd now owns 18 mln shares or 8.876
pct of the company.
newsdesk@afxnews.com
ak

COPYRIGHT

Copyright AFX News Limited 2005. All rights reserved.

MajorShareHolders No. Shares(%) Gartmore 22,016,240(10.86) Schroder 29,171,506 (14.32) UBS AG 21,518,671(10.61) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 107,921,878(53.21)

UBS Increase of Holding

MajorShareHolders No. Shares(%) Gartmore 22,016,240(10.86) Schroder 29,171,506 (14.32) UBS AG 23,797,239 (11.73) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 110,200,446 (54.34)

UBS Increase of Holding

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 29,171,506 (14.32) UBS AG 23,797,239(11.73) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 119,463,550(58.91)

Gartmore Increase of Holdings

Interim Results Wednesday 13th Sept

Ne UK smallcap opening - Osmetech higher on Evanston deal
AFX


LONDON (AFX) - Early progress was seen in Osmetech, 1-1/2 pence firmer at 18, after news that the group has signed a non-exclusive commercial licence with Evanston, Illinois-based Ohmx Corporation to Osmetech's self-assembling monolayer nanotechnology for biosensor use.

newsdesk@afxnews.com

Osmetech PLC signs license

RNS Number:4806K
Osmetech PLC
16 October 2006


Osmetech licenses pharmacogenetic marker for P450-CYP2D6 from EPIDAUROS


Bernried, Germany - October 16, 2006, EPIDAUROS Biotechnologie AG, a leading
provider of pharmacogenetic solutions located in Bernried near Munich, and
Osmetech plc, an international healthcare diagnostics group, jointly announced
today that Osmetech has signed an agreement for a non-exclusive commercial
license to EPIDAUROS' patent application on a specific biomarker related to the
Cytochrome P450 CYP2D6. Financial details are not disclosed.

The agreement covers the genetic variant 2988G>A in the CYP2D6 gene. This
variant could be used in combinatorial analysis with further genetic variants of
CYP2D6 as a predictive marker for impaired enzymatic function putting patients
at higher risk for non-responsiveness or adverse drug reactions. CYP2D6 plays a
role in the metabolism of 25% of the most commonly prescribed drugs to date.
Therefore, the sound analysis of CYP2D6 is important in the course of clinical
drug development to make drug therapy safer and more efficacious.

James White, CEO of OSMETECH added, "This deal marks an important move forward
as we look to gain access to the validated content that exists in the important
area of pharmacogenomics. With the Cystic Fibrosis product already on the market
and our earlier license from LGC, we are in a strong position to take our FDA
cleared electrochemistry-based eSensor(R) array platform into the market with
the launch of our first pharmacogenomic products."

Michael Lutz, CEO of EPIDAUROS added: "We are delighted that Osmetech will use
EPIDAUROS' intellectual property with respect to the variant 2988G>A of CYP2D6
to develop value-adding diagnostic products. This agreement is clearly another
milestone in our strategy to fully exploit the commercial potential of our
existing patent portfolio. We are confident that other companies will require
appropriate licenses on this genetic marker shortly. We also look forward to
exploring additional business opportunities with Osmetech in the near future."


Contact EPIDAUROS:

Dr. Michael Lutz Dr. Stephan Reschauer
Chief Executive Officer Director, Patents & Licensing
Phone: +49 (0)8158 9985 0
Fax: +49 (0)8158 9985 48
Email: contact@epidauros.com

Contact Osmetech plc:

Edward O. Kreusser, Esq.
Vice President Intellectual Property and Legal Affairs
Phone: +1 626 463 2000 ext. 8017
Fax: +1 626 463 2012
Email: Ed.kreusser@osmetech.com


About Osmetech plc
(www.osmetech.com)

Osmetech plc is an AIM-listed public company on the London Stock Exchange. The
company is a fast developing, international diagnostics business with operations
in Atlanta, Boston and Pasadena in the US, serving the high growth, near patient
testing market targeting small to medium sized hospitals. Osmetech operates in
two business areas, namely Molecular Diagnostics and Critical Care Diagnostics.
Osmetech has launched eSensor(R), an FDA cleared electrochemistry-based array
system, for Cystic fibrosis carrier detection and will launch a number of
pharmacogenomic assays utilizing our proprietary technology in the near future.


About EPIDAUROS Biotechnologie AG
(www.epidauros.com)

EPIDAUROS Biotechnologie AG is a leading provider of tailor-made pharmacogenetic
solutions in the area of clinical drug development. The company investigates the
individual genetic profile that influences a person's response to a drug in
order to make drug development and therapy safer and more efficient. EPIDAUROS
examines and characterizes variations (polymorphisms) of genes that encode for
drug transporter proteins, drug metabolizing enzymes and drug targets, e.g.
receptors.

EPIDAUROS' business activities range from scientific pharmacogenetic
consultancy, conduct of logistics for sample collection and shipment, sample
processing and genetic testing in its own laboratory, up to data analysis and
submission-ready reporting. In addition, provision of services includes
development of new assays for genetic testing and extensive analysis of
pharmacogenetic data, e.g. with regard to haplotypes (linked genetic markers).

EPIDAUROS explores new polymorphisms with pharmacogenetic relevance in close
collaboration with leading academic institutions. In addition, the company also
offers a concept for the development of drugs with companion diagnostics to the
pharmaceutical industry. Moreover, EPIDAUROS develops genetic tests for routine
use together with diagnostics companies.


For further information, please contact:

EPIDAUROS Biotechnologie AG
Am Neuland 1, D-82347 Bernried
Phone: +49 (0)8158 9985 0
Fax: +49 (0)8158 9985 48
Email: contact@epidauros.com
www.epidauros.com

Osmetech Inc.
DBA as Clinical Micro Sensors
757 South Raymond Street
Pasadena, CA 91105
USA
Phone: +1 626 463 2000
Fax: +1 626 463 2012
Email: information@osmetech.com
www.osmetech.com



This information is provided by RNS
The company news service from the London Stock Exchange

END
NRAGUGRPUUPQGMW

MajorShareHolders No. Shares(%) Gartmore 31,279,344(15.42) Schroder 30,516,506(15.05) UBS AG 23,797,239(11.73) Universities S S LTD 8,900,000(4.39) Pershing Keen 5,870,773 (2.89) Roche 2,444,688 (1.21) EBMF Ltd 18,000,000(8.88) Total 120,808,550(59.56)

Schroder Investment Management Increase Stake

Bangersmam,

Is this the only share you own ?????? Talk about flogging a dead horse, since the thread was started by you nearly a year ago the share price has dropped by around 10% despite you continually trying to scrape up interest in it.

Do what I did - take the loss on the chin and recoup the money in more viable companies.

Dont judge others by your own poor trading standards, i have no loss to take- only profits.

Looking good for a further breakout soon.

hobbsts

Selling up was a very stupid thing to do...

everyone is entitled to their opinion ...................I personally did not want to hold for year upon year to recoup my loss. You win some, you lose some. Holding shares is all about making money and not getting emotionally involved with the company as is what is happening on this thread.

A few more clueless holders taken out in yesterdays tree shake- paving the way for further rises.

Looking good for 25p soon!

hobbst, what a clueless tosser

DITCHPIG

Good of you to let the world see what a great command you have of the english language.

hobbst, what a clueless tosser

Been reading all the personal abuse that both DITCHPIG and bangers(mam) get up to on ADVFN, while ramping OMH - their only shareholding. No wonder that people on that website are fed up with their antics and have even set up a thread to try and exclude people like these, in order to get a level debate.

Come on Money AM, must be time to get rid of these idiots from your bulletin boards.